In this respect, several clinical trials with β-thalassemia and/or sickle-cell anemia patients are ongoing using HbF inducers, such as NCT01245179 (based on the HDAC inhibitor Panobinostat) [74], NCT00790127 (based on 2,2-dimethylbutyrate, HQK-1001) [50] and NCT03877809 (based on the mTOR inhibitor rapamycin) [58]. Here, HDAC9 is linked to sickle cell disease.